Cargando…
Mechanisms that lessen benefits of β-secretase reduction in a mouse model of Alzheimer's disease
The β-secretase enzyme BACE1 (β-site amyloid precursor protein-cleaving enzyme 1), which initiates amyloid-β (Aβ) production, is an excellent therapeutic target for Alzheimer's disease (AD). However, recent evidence raises concern that BACE1-inhibiting approaches may encounter dramatic declines...
Autores principales: | Devi, L, Ohno, M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3731791/ https://www.ncbi.nlm.nih.gov/pubmed/23880880 http://dx.doi.org/10.1038/tp.2013.59 |
Ejemplares similares
-
β-Secretases, Alzheimer's Disease, and Down Syndrome
por: Webb, Robin L., et al.
Publicado: (2012) -
The Alzheimer's disease β-secretase enzyme, BACE1
por: Cole, Sarah L, et al.
Publicado: (2007) -
Targeted Genetic Reduction of Mutant Huntingtin Lessens Cardiac Pathology in the BACHD Mouse Model of Huntington's Disease
por: Park, Saemi, et al.
Publicado: (2021) -
C/EBPβ regulates delta-secretase expression and mediates pathogenesis in mouse models of Alzheimer’s disease
por: Wang, Zhi-Hao, et al.
Publicado: (2018) -
Mechanisms Underlying Insulin Deficiency-Induced Acceleration of β-Amyloidosis in a Mouse Model of Alzheimer's Disease
por: Devi, Latha, et al.
Publicado: (2012)